Action DCPH DECIPHERA PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Deciphera Pharmaceuticals, Inc.

Actions

DCPH

US24344T1016

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 10/06/2024 		Varia. 5j. Varia. 1 janv.
25,59 USD +0,08 % Graphique intraday de Deciphera Pharmaceuticals, Inc. -.--% +58,65 %
11/06 Deciphera Pharmaceuticals, Inc. annonce des changements au sein de son conseil d'administration et de ses comités CI
03/06 Deciphera Pharmaceuticals annonce la présentation orale des résultats de l'étude pivotale de phase 3 Motion sur le vimseltinib chez les patients atteints de tumeur à cellules géantes ténosynoviale (TGCT) lors de la réunion annuelle 2024 de l'Asco et la publication en ligne dans le Lancet CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion
Deciphera Pharmaceuticals, Inc. Announces Board and Committee Changes
Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Global BMI Index
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P TMI Index
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Biotechnology Select Industry Index
Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Biotechnology Index
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor At the 2024 Asco Annual Meeting and Online Publication in the Lancet
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH
North American Morning Briefing : Traders Wait for -2-
North American Morning Briefing : More Earnings -2-
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH
US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Top Midday Gainers
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action DCPH
  4. Actualités Deciphera Pharmaceuticals, Inc.
  5. Autres langues